Pro12Ala substitution in the peroxisome proliferator-activated receptor gamma (PPARγ) gene and non-alcoholic fatty liver disease

The aim of this study was to analyze the relationship between Pro12Ala substitution in the peroxisome proliferator-activated receptor gamma (PPARy) gene and non-alcoholic fatty liver disease (NAFLD). Ninety-seven patients with NAFLD and 51 healthy subjects were included in the study. The height, weight, abdominal wall fat thickness, blood pressure, serum triglyceride, total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose level, hip and waist circumference, and body fat percentage were measured. The PPARγ Pro12Ala genotypes were analyzed using oligonucleotide microarray. Among the NAFLD patients, 11.34% (11/97) had the GC genotype (Pro/Ala) and 88.66% (86/97) had the C genotype (Pro). Among the healthy control group, 5.88% (3/51) had the GC genotype and 94.12% (48/51) had the C genotype. There was no significant difference in the distribution of PPARγ Pro12Ala polymorphism between the NAFLD patients and control subjects. There was no significant difference between PPARγ Pro12Ala polymorphism distribution or blood pressure, weight, body mass index, hip circumference, waist circumference, waist-hip ratio, percentage of body fat, abdominal wall fat thickness, fasting serum glucose, triglyceride, or total cholesterol when compared between these genotypes. No association between PPARγ Pro12Ala substitution and non-alcoholic fatty liver disease was found in the study.